Eris Lifesciences LimitedERISCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data

₹1,144.40

MCap ₹15,859 Cr · P/E 82.4

Eris Lifesciences Limited — Stock analysis & AI research Eris Lifesciences Limited — Multibagger AI analysis Eris Lifesciences Limited — Seasonality — best & worst months Eris Lifesciences Limited — Technical indicators & charts Eris Lifesciences Limited — Technical setup — score, trend, support & resistance Eris Lifesciences Limited — Falling Wedge pattern forming Eris Lifesciences Limited — Live exchange announcements

📋 High Operating Margin Stocks 📋 Stocks Cheaper Than Their Industry 📋 Small Cap Stocks List 📈 RSI Oversold Stocks 📈 New 52-Week Low Stocks 📈 Lowest Technical Score 📈 Multi-Timeframe Bearish Stocks 📈 Stocks Near 52-Week Low 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹444 Cr

Sales · Jun 2026

-23.3% YoY

₹120 Cr

Operating Profit · Jun 2026

-44.6% YoY

27.0%

OPM % · Jun 2026

-27.8% YoY

₹48 Cr

Net Profit · Jun 2026

-51.7% YoY

₹3.49

EPS · Jun 2026

-52.5% YoY

📝 Eris Lifesciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Eris Lifesciences Limited reported revenue of ₹444 crore for the quarter ended June 2026 (Q1 FY27), down 23.3% from ₹579 crore in the same quarter last year, and up 60.1% sequentially over the March 2026 quarter.

Net profit fell 51.7% year-on-year to ₹48 crore, from ₹100 crore. Earnings per share (EPS) came in at ₹3.49.

Operating profit stood at ₹120 crore — an operating margin (OPM) of 27.0%, compared with 37.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Eris Lifesciences Limited posted revenue of ₹1,822 crore, a growth of 7.3% over FY25, with a net profit of ₹244 crore (up 215.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,687 crore with a net profit of ₹192 crore.

Valuation snapshot

At the current price of ₹1,144.40, ERIS has a market capitalisation of ₹15,859 crore and a trailing P/E of about 82.4.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 24th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 54.14%, foreign institutional investors (FIIs) 5.75%, domestic institutional investors (DIIs) 20.72%, public shareholders 19.40% of Eris Lifesciences Limited.

Promoter holding rose from 53.92% to 54.14% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹15,859 Cr

Current Price ?

₹1,144.4

P/E ?

82.45above ind

Industry P/E ?

35.00

P/B ?

4.96

P/S ?

9.40

P/FCF ?

30.80

Enterprise Value ?

₹17,960 Cr

EV/EBITDA ?

34.81

PEG ?

N/A

Earnings Yield ?

2.0%

Dividend Yield ?

0.63%

Profitability & Returns

Sales (TTM) ?

₹1,687 Cr

OPM ?

30.6%

Profit after tax (TTM) ?

₹192 Cr

EPS (TTM) ?

₹13.88

ROCE ?

11.0%

ROE ?

6.0%

ROA ?

3.3%

Growth

Sales — latest qtr ?

₹444 Cr

PAT — latest qtr ?

₹48 Cr

YoY qtr sales growth ?

-23.3%

YoY qtr profit growth ?

-51.7%

Sales growth (3y) ?

11%

Sales growth (5y) ?

10%

Profit growth (3y) ?

-14%

Profit growth (5y) ?

-6%

Financial Health

Debt ?

₹2,101 Cr

Debt to Equity ?

0.66

Interest Coverage ?

2.6

Current Ratio ?

N/A

Ownership

Promoter holding ?

54.14%

Change in promoter holding ?

-0.69%

Pledged percentage ?

N/A

Market

Return 3 months ?

-21.4%

Return 6 months ?

-20.8%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	332	315	411	410	324	341	457	437	400	405	579	650	315	277	444	-23.3%	+60.1%
Operating Profit	126	111	156	144	74	79	123	143	100	121	216	297	77	22	120	-44.6%	+450.5%
Other Income	3	4	4	7	3	20	5	6	8	17	23	24	25	27	26	+16.3%	-2.2%
Interest	3	3	7	7	15	29	56	56	55	53	45	46	45	43	42	-6.6%	-1.3%
Depreciation	16	17	20	25	28	29	46	46	47	43	38	39	39	39	40	+6.3%	+3.0%
Profit Before Tax	110	96	133	120	35	42	27	46	6	41	156	235	4	-33	64	-59.0%	+295.7%
Net Profit	99	88	111	118	32	40	17	28	2	30	100	150	3	-9	48	-51.7%	+661.6%
EPS	7.31	6.46	8.14	8.66	2.33	2.90	1.25	2.06	0.13	2.24	7.34	10.98	0.23	-0.62	3.49	-52.5%	+662.9%
OPM %	38.1%	35.4%	37.8%	35.3%	22.9%	23.3%	27.0%	32.7%	24.9%	29.9%	37.4%	45.6%	24.5%	7.9%	27.0%	-27.8%	+241.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹1,698 Cr	₹1,822 Cr	₹1,687 Cr	+7.3%
Operating Profit	₹487 Cr	₹612 Cr	₹516 Cr	+25.9%
OPM %	28.66%	33.61%	30.58%	+17.3%
NPM %	4.56%	13.40%	11.40%	+193.9%
Other Income	₹36 Cr	₹98 Cr	₹102 Cr	+176.9%
Depreciation	₹182 Cr	₹154 Cr	₹157 Cr	-15.1%
Interest	₹220 Cr	₹180 Cr	₹177 Cr	-18.5%
EBIT	₹305 Cr	₹458 Cr	₹359 Cr	+50.3%
PBT	₹120 Cr	₹362 Cr	₹270 Cr	+201.6%
Tax	₹43 Cr	₹142 Cr	₹102 Cr	+233.3%
Net Profit	₹77 Cr	₹244 Cr	₹192 Cr	+215.4%
EPS	₹5.68	₹17.93	₹14.08	+215.7%
Material Cost	₹543 Cr	₹417 Cr	₹434 Cr	-23.2%
Employee Cost	₹362 Cr	₹262 Cr	₹259 Cr	-27.6%
Extraordinary Items	—	₹-15 Cr	₹-15 Cr	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	14	14	14	14	+0.0%
Reserves	2,208	2,510	2,501	3,182	+27.2%
Borrowings	317	2,572	2,245	2,101	-6.4%
Other Liabilities	245	254	463	481	+3.9%
Total Liabilities	2,784	5,350	5,222	5,778	+10.6%
Fixed Assets	898	1,516	2,412	2,353	-2.4%
CWIP	0	1	0	0	—
Investments	997	1,619	991	1,414	+42.7%
Other Assets	889	2,214	1,819	2,011	+10.6%
Total Assets	2,784	5,350	5,222	5,778	+10.6%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	322	336	702	564	-19.7%
Cash from Investing Activity	-513	-2,492	-359	-694	-93.3%
Cash from Financing Activity	194	2,160	-310	71	+122.9%
Net Cash Flow	3	4	32	-59	-284.4%
Free Cash Flow	11	-13	694	515	-25.8%
CFO/OP	79%	90%	147%	104%	-29.3%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	63	59	51	62	+21.6%
Inventory Days	98	119	140	71	-49.3%
Days Payable	128	143	158	128	-19.0%
Cash Conversion Cycle	33	35	33	4	-87.9%
Working Capital Days	52	-413	-99	-145	-46.5%
ROCE %	20%	10%	7%	11%	+57.1%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	54.83%	54.85%	54.85%	53.92%	54.14%	+0.4%
FIIs	8.39%	7.21%	6.85%	6.39%	5.75%	-10.0%
DIIs	18.18%	19.36%	20.31%	20.35%	20.72%	+1.8%
Public	18.59%	18.57%	17.97%	19.33%	19.40%	+0.4%
No. of Shareholders	52,225	59,438	54,713	51,656	50,798	-1.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUNPHARMA Sun Pharmaceutical	₹1,840.00	441,478	36.5	59,911	12,104	29.8%	20.2%	11.2%	5.1%	10.5%	27.0%
2	DIVISLAB Divi's Laboratories	₹9,235.00	245,160	83.8	11,230	2,925	35.3%	26.0%	12.8%	16.7%	27.8%	65.5%
3	TORNTPHARM Torrent Pharmaceuticals	₹4,931.00	187,559	87.1	15,723	2,156	33.0%	13.7%	21.4%	11.9%	54.8%	3.3%
4	ZYDUSLIFE Zydus Lifesciences	₹1,162.20	115,930	23.2	27,148	5,070	31.2%	18.7%	16.8%	12.0%	16.2%	14.5%
5	CIPLA Cipla	₹1,366.00	110,353	32.7	28,324	3,356	18.7%	11.8%	2.2%	-26.7%	2.3%	-39.2%
6	LAURUSLABS Laurus Labs	₹1,969.00	106,387	97.2	7,270	1,090	28.0%	15.0%	22.7%	147.9%	29.1%	123.9%
7	DRREDDY Dr. Reddy's	₹1,165.50	97,085	29.3	28,704	3,273	15.3%	11.4%	-10.4%	-25.8%	-5.6%	-69.2%
8	AUROPHARMA Aurobindo Pharma	₹1,679.80	96,652	26.2	34,935	3,711	20.3%	10.6%	6.1%	0.6%	16.3%	25.2%
9	LUPIN Lupin	₹2,095.00	95,797	17.9	27,958	5,356	31.5%	19.2%	23.1%	62.0%	31.9%	87.8%
10	MANKIND Mankind Pharma	₹2,280.00	94,174	46.1	14,738	2,067	26.0%	14.0%	16.3%	-3.7%	12.9%	29.1%
11	GLENMARK Glenmark Pharmaceuticals	₹2,419.20	68,276	38.0	17,737	1,797	27.0%	10.1%	-61.2%	-67.4%	23.1%	927.9%
12	ALKEM Alkem Laboratories	₹5,243.50	62,694	29.1	15,081	2,187	20.1%	14.5%	13.5%	7.6%	10.9%	-21.6%
13	ABBOTINDIA Abbott India	₹25,860.00	54,951	34.0	7,005	1,615	28.1%	23.1%	8.1%	9.7%	4.4%	17.2%
14	IPCALAB Ipca Laboratories	₹1,964.20	49,833	38.0	10,125	1,379	22.0%	13.6%	7.9%	55.0%	20.8%	82.2%
15	GLAND Gland Pharma	₹2,935.90	48,433	47.1	6,431	1,028	25.3%	16.0%	-64.7%	-48.4%	22.3%	96.7%
16	AJANTPHARM Ajanta Pharma	₹3,398.90	42,472	37.4	5,777	1,135	25.4%	19.7%	17.3%	14.8%	24.8%	30.9%
17	JBCHEPHARM J. B.	₹2,416.10	38,793	53.4	4,148	709	26.7%	17.1%	5.9%	7.5%	-4.8%	-30.7%
18	EMCURE EMCURE PHARMACEUTICALS	₹1,975.10	37,470	37.0	9,684	1,019	20.4%	10.5%	16.6%	33.1%	22.8%	36.0%
19	WOCKPHARMA Wockhardt	₹2,021.50	32,848	92.5	3,133	353	19.9%	11.3%	-2.3%	342.1%	25.9%	199.1%
20	NEULANDLAB Neuland Laboratories	₹23,455.00	30,093	82.7	2,023	365	28.4%	18.0%	37.0%	40.2%	136.3%	666.0%
21	PPLPHARMA Piramal Pharma	₹211.50	28,024	113.5	9,206	247	11.0%	2.7%	-3.1%	-37.9%	17.4%	-161.3%
22	GRANULES Granules India	₹885.60	21,945	32.8	5,633	663	22.7%	11.8%	19.7%	18.8%	22.0%	59.3%
23	CAPLIPOINT Caplin Point	₹2,752.60	20,923	31.4	2,287	678	34.8%	29.7%	12.9%	20.2%	19.6%	18.8%
24	ERIS Eris Lifesciences	₹1,358.00	18,820	29.0	3,230	666	35.2%	20.6%	8.2%	72.6%	13.0%	14.6%
25	ASTRAZEN AstraZeneca Pharma	₹6,755.00	16,888	99.6	2,432	170	9.4%	7.0%	32.7%	62.1%	29.7%	-32.1%

❓ Frequently asked questions

What was Eris Lifesciences Limited's revenue in Q1 FY27?

What was Eris Lifesciences Limited's net profit in Q1 FY27?